$165.34
0.60% yesterday
Nasdaq, Jun 13, 10:11 pm CET
ISIN
US6323071042
Symbol
NTRA
Sector
Industry

Natera, Inc. Stock price

$165.34
+13.06 8.58% 1M
-1.21 0.73% 6M
+7.04 4.45% YTD
+54.55 49.24% 1Y
+122.05 281.94% 5Y
+142.60 627.09% 10Y
+142.60 627.09% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.99 0.60%
ISIN
US6323071042
Symbol
NTRA
Sector
Industry

Key metrics

Market capitalization $22.58b
Enterprise Value $21.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 254.32
EV/Sales (TTM) EV/Sales 11.83
P/S ratio (TTM) P/S ratio 12.33
P/B ratio (TTM) P/B ratio 18.13
Revenue growth (TTM) Revenue growth 51.50%
Revenue (TTM) Revenue $1.83b
EBIT (operating result TTM) EBIT $-227.16m
Free Cash Flow (TTM) Free Cash Flow $85.19m
Cash position $991.60m
EPS (TTM) EPS $-1.40
P/E forward negative
P/S forward 11.32
EV/Sales forward 10.86
Short interest 4.59%
Show more

Is Natera, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Natera, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Natera, Inc. forecast:

21x Buy
95%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Natera, Inc. forecast:

Buy
95%
Sell
5%

Financial data from Natera, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,831 1,831
52% 52%
100%
- Direct Costs 700 700
16% 16%
38%
1,131 1,131
86% 86%
62%
- Selling and Administrative Expenses 914 914
38% 38%
50%
- Research and Development Expense 445 445
36% 36%
24%
-194 -194
46% 46%
-11%
- Depreciation and Amortization 33 33
27% 27%
2%
EBIT (Operating Income) EBIT -227 -227
41% 41%
-12%
Net Profit -190 -190
48% 48%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Natera, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Natera, Inc. Stock News

Positive
24/7 Wall Street
9 days ago
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Neutral
Business Wire
10 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, and pan-cancer immunotherapy monito...
Neutral
Business Wire
12 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study analyzed the performance of Signatera Genome in a cohort of 392 patients (...
More Natera, Inc. News

Company Profile

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.

Head office United States
CEO Stephen Chapman
Employees 4,429
Founded 2004
Website www.natera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today